Expansion of Treatment for Hepatitis C Virus Infection
Authors: Dev Katarey
Journal: Annals of Internal Medicine (2018)

Letters20 March 2018Expansion of Treatment for Hepatitis C Virus InfectionDev Katarey, MBBS, MSc, PGCert(HBE)Dev Katarey, MBBS, MSc, PGCert(HBE)Royal Sussex County Hospital, Brighton, United Kingdom (D.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0696 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I read Kattakuzhy and colleagues' (1) article on the efficacy of HCV treatment provided by NPs, PCPs, and specialist physicians with great interest. Although I agree in principle with the authors' conclusions, making an informed decision on the efficacy of using other treatment providers on the basis of these data is difficult.The age of direct-acting antivirals has ensured that most patients receiving these drugs will attain a sustained virologic response (SVR). This may be especially true with the advent of glecaprevir and pibrentasvir, because phase 2 trials (such as MAGELLAN-1 [Glecaprevir and Pibrentasvir for 12 or ...References1. Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, et al; the ASCEND Providers. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017;167:311-8. [PMID: 28785771]. doi:10.7326/M17-0118 LinkGoogle Scholar2. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389-97. [PMID: 28128852] doi:10.1002/hep.29081 CrossrefMedlineGoogle Scholar3. Gilead Sciences. Harvoni U.S. full prescribing information. June 2016. Accessed at www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf on 20 August 2017. Google Scholar Author, Article, and Disclosure InformationAffiliations: Royal Sussex County Hospital, Brighton, United Kingdom (D.K.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0696. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoExpansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers Sarah Kattakuzhy , Chloe Gross , Benjamin Emmanuel , Gebeyehu Teferi , Veronica Jenkins , Rachel Silk , Elizabeth Akoth , Aurielle Thomas , Charisse Ahmed , Michelle Espinosa , Angie Price , Elana Rosenthal , Lydia Tang , Eleanor Wilson , Soren Bentzen , Henry Masur , Shyam Kottilil , and Expansion of Treatment for Hepatitis C Virus Infection Max J. Romano Expansion of Treatment for Hepatitis C Virus Infection Benjamin Emmanuel , Henry Masur , Shyam Kottilil , and Sarah Kattakuzhy Metrics 20 March 2018Volume 168, Issue 6Page: 457KeywordsAntiviralsDrug interactionsDrugsForecastingHealth careHepatitis C virusInfectious hepatitisPhase 2 trialsSafetySystemic vascular resistance ePublished: 20 March 2018 Issue Published: 20 March 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...